The Filing Desk

Mangoceuticals vs Sera Prognostics

Mangoceuticals MGRX · Sera Prognostics SERA · Health Care Services

Mangoceuticals reported revenue of $0 million in fiscal 2025, 5.0 times Sera Prognostics' $0 million in fiscal 2025. Mangoceuticals' revenue fell 26.0% in its latest year, and Sera Prognostics' grew 5.2%. Mangoceuticals had an operating margin of -3954.3%, against -45066.7% at Sera Prognostics.

Side by side

MangoceuticalsSera Prognostics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$0M$0M
Revenue growth−26.0%5.2%
Revenue growth a year, last 5 years——
Gross margin54.9%−102.5%
Operating margin−3,954.3%−45,066.7%
Net margin−4,526.8%−39,417.3%
Free cash flow—−$26M
Free cash flow margin—−32,529.6%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count408.9%43.8%
Last close$0.13$1.89
P/E at the last close——
Insider trades, last 12 months—sold $514,580
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
MangoceuticalsSera Prognostics
Operating margin
Percent of revenue
MangoceuticalsSera Prognostics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
MangoceuticalsSera Prognostics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Mangoceuticals and Sera Prognostics pages.